Speaking via Skype, Lubetkin pointed to a clear link between the lack of exercise and the bad health consequences of obesity.
VOA: standard.2010.08.10
That, generally speaking, is bad news for other obesity drug companies like Orexigen, which faces an FDA panel in December, and Arena Pharmaceuticals, whose lorcaserin was rejected last week.